Creative Medical Technology Holdings, Inc. Common Stock (CELZ) — 分析摘要
Creative Medical Technology Holdings, Inc. Common Stock（CELZ）的市值为5.54百万美元，最近一年的营收同比增长了-45.5%。净利润率为-99916.8%。当前市盈率为-1.0倍。
核心要点
- 营收同比变化-45.5%
- 净利润率-99916.8%
- 市盈率-1.0倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，CELZ的营收增长为-45.5%，市盈率为-1.0倍。
Creative Medical Technology Holdings, Inc. Common Stock (CELZ)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -198049.6% — 严重经营亏损
净利率为 -192066.3% — 亏损超过收入（可能含一次性费用）
营收较上一期下降 50.0%。
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
4
总部
PHOENIX, AZ
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。